693 related articles for article (PubMed ID: 17355844)
1. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for chemotherapy-induced emesis.
Navari RM; Province PS
Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
10. New antiemetic drugs.
Roila F; Fatigoni S
Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Celio L; Agustoni F; Testa I; Dotti K; de Braud F
Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
[TBL] [Abstract][Full Text] [Related]
13. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Wang SY; Yang ZJ; Zhang L
Asian Pac J Cancer Prev; 2014; 15(22):9587-92. PubMed ID: 25520071
[TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis of chemotherapy-induced vomiting and nausea].
Tóth J; Szántó J
Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
[TBL] [Abstract][Full Text] [Related]
16. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Ellebaek E; Herrstedt J
Curr Opin Support Palliat Care; 2008 Mar; 2(1):28-34. PubMed ID: 18685391
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
[TBL] [Abstract][Full Text] [Related]
18. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
